Skip to Main Content

While much of the world is understandably focused on the new coronavirus’s emergence in China, three recent developments involve the potential expansion of treatments for an entrenched disease there: cancer.

One biotech is making it easier for patients to keep taking its checkpoint inhibitor, one pharma giant has won approval for a new type of cancer its targeted drug therapy can treat, and another major pharma has won the go-ahead for a combination therapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!